A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2017 Planned primary completion date changed from 1 Oct 2013 to 1 Mar 2017.
    • 19 May 2016 Primary endpoint has been met. (Overall survival), as per an article published in the Cancer.
    • 19 May 2016 Results published in the Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top